NLSP - NLS Pharmaceutics AG

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
9,601
8,977
5,919
99.58
1,702
Selling general and administrative
6,405
6,506
5,941
2,200
2,495
Total operating expenses
16,006
15,482
11,861
2,299
4,197
Operating income or loss
-16,006
-15,482
-11,861
-2,299
-4,197
Interest expense
9.181
100.866
68.134
233.7
819.711
Total other income/expenses net
31.53
-912.45
-17.323
-328.365
-430.396
Income before tax
-15,984
-16,496
-11,946
-2,861
-5,447
Income from continuing operations
-15,984
-16,496
-11,946
-2,861
-5,447
Net income
-15,984
-16,496
-11,946
-2,861
-5,447
Net income available to common shareholders
-15,984
-16,496
-11,946
-2,861
-5,447
Basic EPS
-
-
-1.00
-0.27
-0.46
Diluted EPS
-
-
-1.00
-0.27
-0.46
Basic average shares
-
-
11,902
11,779
11,779
Diluted average shares
-
-
11,902
11,779
11,779
EBITDA
-
-16,383
-11,868
-2,628
-4,627